Top Stock Reports for GE Aerospace, Shell & McKesson
View original at finance.yahoo.comTop Stock Reports for GE Aerospace, Shell & McKesson Tuesday, March 17, 2026 The Zacks Research Daily presents the best research output of our analyst team…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Elite Pharmaceuticals remains sensitive to generic pricing pressure, DEA quota and API supply constraints, and customer concentration
60% confidenceGeospace's valuation implies investors are pricing risk, leaving upside if contract delivery improves visibility
60% confidenceMcKesson faces risks from revenue concentration with large customers, regulatory headwinds such as IRA and DSCSA, and execution challenges from the Medical-Surgical separation and ongoing M&A integration
60% confidenceShell achieved structural cost reductions ahead of schedule and portfolio simplification that have improved efficiency and balance-sheet flexibility
60% confidenceRising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for GE Aerospace
60% confidenceShell's net debt increased, while Chemicals and Renewables continue to weigh on returns amid weak margins
60% confidenceGeospace's liquidity has declined as working capital builds for contracts and receivable concentration adds risk
60% confidenceFor Shell, strengths are offset by cyclical and segment-specific risks, justifying a neutral stance
60% confidenceMcKesson's strategic acquisitions such as PRISM and Core Ventures enhance its oncology footprint
60% confidencePotential LNG oversupply and geopolitical volatility add uncertainty for Shell
60% confidenceElite Pharmaceuticals' stable base from amphetamine IR and ER generics supports cash flow, while new launches and a growing pipeline enhance revenue visibility
60% confidenceRising U.S. & international defense budgets, geopolitical tensions, positive airline & airframer dynamics and robust demand for commercial air travel augur well for GE Aerospace
60% confidenceShell demonstrated resilient cash generation in 2025, delivering robust operating and free cash flows, supporting shareholder returns
60% confidenceGeospace's near-term results reflect cyclical energy demand and margin pressure from low rental utilization
60% confidenceMcKesson's RxTS provides recurring, high-margin revenue streams
60% confidenceElite Pharmaceuticals' expansion into opioid analgesics diversifies the opportunity set
60% confidenceShell's structural cost reductions achieved ahead of schedule and portfolio simplification have improved efficiency and balance-sheet flexibility
60% confidenceShell's earnings and revenue declined year over year, highlighting exposure to commodity price cycles
60% confidenceMcKesson's strong cash flow generation and disciplined capital allocation underpin long-term adjusted EPS growth of 12-14%
60% confidenceMcKesson is delivering record revenues and expanding margins, supported by growth in specialty pharmaceuticals, oncology services, RxTS, and GLP-1 distribution
60% confidenceGE Aerospace has been dealing with high costs and expenses related to certain projects and restructuring activities, which are likely to affect its margins and profitability
60% confidenceGeospace Technologies offers exposure to long-cycle infrastructure and energy markets across Smart Water, Intelligent Industrial and Energy Solutions
60% confidenceGeospace's $90 million PRM contract provides revenue visibility, and Pioneer land nodes expand GEOS' role in seismic exploration
60% confidenceShell's earnings and revenue declined year over year, highlighting exposure to commodity price cycles
60% confidenceGeospace's Intelligent Industrial is developing subscription-based security products, such as the Heartbeat Detector, that add predictable revenue
60% confidenceGeospace Technologies' liquidity has declined as working capital builds for contracts and receivable concentration adds risk
60% confidenceGeospace Technologies' $90 million PRM contract provides revenue visibility, and Pioneer land nodes expand GEOS' role in seismic exploration
60% confidenceMcKesson's acquisitions of PRISM and Core Ventures enhance its oncology footprint
60% confidenceShell's strengths are offset by cyclical and segment-specific risks, justifying a neutral stance
60% confidenceGE Aerospace has been dealing with high costs and expenses related to certain projects and restructuring activities, which are likely to affect its margins and profitability
60% confidence